Emcure Pharmaceuticals: Difference between revisions

Add links
From Startupedia
VisualWikitext
Creating Emcure Pharmaceuticals
 
Fixed ref issue
 
(One intermediate revision by the same user not shown)
Line 43: Line 43:


== Origin & Founding Story ==
== Origin & Founding Story ==
[[File:Namita Thapar Emcure.jpg|right|thumb|250px|Namita Thapar, the Executive director of Emcure Pharmaceuticals]]
[[File:Namita Thapar Emcure.png|right|thumb|250px|Namita Thapar, the Executive director of Emcure Pharmaceuticals]]
Emcure Pharmaceuticals was founded in 1981 by Satish Ramanlal Mehta in [[Pune]], [[Maharashtra]]. Starting as a contract manufacturer for multinational pharmaceutical companies, Mehta leveraged his education from [[IIM Ahmedabad]] and family business background to pivot Emcure towards developing branded generic formulations. With an initial bank loan of ₹3 lakh, Mehta built a company focused on innovation, particularly in complex APIs and biotherapeutics. By the 1990s, Emcure transitioned into producing generics, and by 2006, it secured licensing agreements with global giants like [[Bristol-Myers Squibb]] and [[Gilead Sciences]]. The company’s emphasis on research and development, coupled with strategic partnerships, enabled its expansion into over 70 countries.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder | IPO | Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref><ref>{{cite web |title=Emcure Pharmaceuticals - Crunchbase Company Profile |url=https://www.crunchbase.com/organization/emcure-pharmaceuticals |website=Crunchbase |access-date=26 May 2025}}</ref>
Emcure Pharmaceuticals was founded in 1981 by Satish Ramanlal Mehta in [[Pune]], [[Maharashtra]]. Starting as a contract manufacturer for multinational pharmaceutical companies, Mehta leveraged his education from [[IIM Ahmedabad]] and family business background to pivot Emcure towards developing branded generic formulations. With an initial bank loan of ₹3 lakh, Mehta built a company focused on innovation, particularly in complex APIs and biotherapeutics. By the 1990s, Emcure transitioned into producing generics, and by 2006, it secured licensing agreements with global giants like [[Bristol-Myers Squibb]] and [[Gilead Sciences]]. The company’s emphasis on research and development, coupled with strategic partnerships, enabled its expansion into over 70 countries.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder, IPO, Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref><ref>{{cite web |title=Emcure Pharmaceuticals - Crunchbase Company Profile |url=https://www.crunchbase.com/organization/emcure-pharmaceuticals |website=Crunchbase |access-date=26 May 2025}}</ref>


== Timeline ==
== Timeline ==
Line 52: Line 52:
| 1981 || Emcure Pharmaceuticals founded by Satish Ramanlal Mehta in Pune with a ₹3 lakh bank loan.<ref>{{cite web |title=How Emcure Pharma owner built a Rs 6,000 Cr business empire |url=https://yourstory.com/2021/08/emcure-pharma-satish-mehta-rs-6000-cr-business-empire |website=YourStory |date=19 August 2021 |access-date=26 May 2025}}</ref>
| 1981 || Emcure Pharmaceuticals founded by Satish Ramanlal Mehta in Pune with a ₹3 lakh bank loan.<ref>{{cite web |title=How Emcure Pharma owner built a Rs 6,000 Cr business empire |url=https://yourstory.com/2021/08/emcure-pharma-satish-mehta-rs-6000-cr-business-empire |website=YourStory |date=19 August 2021 |access-date=26 May 2025}}</ref>
|-
|-
| 1990s || Transitioned from contract manufacturing to producing generic drugs.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder | IPO | Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref>
| 1990s || Transitioned from contract manufacturing to producing generic drugs.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder, IPO, Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref>
|-
|-
| 2006 || Signed licensing agreements with [[Bristol-Myers Squibb]] for Atazanavir and [[Gilead Sciences]] for Tenofovir.<ref>{{cite web |title=Emcure Pharmaceuticals - Crunchbase Company Profile |url=https://www.crunchbase.com/organization/emcure-pharmaceuticals |website=Crunchbase |access-date=26 May 2025}}</ref>
| 2006 || Signed licensing agreements with [[Bristol-Myers Squibb]] for Atazanavir and [[Gilead Sciences]] for Tenofovir.<ref>{{cite web |title=Emcure Pharmaceuticals - Crunchbase Company Profile |url=https://www.crunchbase.com/organization/emcure-pharmaceuticals |website=Crunchbase |access-date=26 May 2025}}</ref>
Line 58: Line 58:
| 2006 || Received US FDA approval for solid dosage facility at Hinjawadi, Pune.<ref>{{cite web |title=Emcure Pharmaceuticals |url=https://www.emcure.com |website=Emcure |access-date=26 May 2025}}</ref>
| 2006 || Received US FDA approval for solid dosage facility at Hinjawadi, Pune.<ref>{{cite web |title=Emcure Pharmaceuticals |url=https://www.emcure.com |website=Emcure |access-date=26 May 2025}}</ref>
|-
|-
| 2012 || Signed agreement with [[Roche]] to manufacture anticancer drugs Herceptin and Mabthera in India.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder | IPO | Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref>
| 2012 || Signed agreement with [[Roche]] to manufacture anticancer drugs Herceptin and Mabthera in India.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder, IPO, Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref>
|-
|-
| 2013 || Launched health foods venture in partnership with cricketer [[MS Dhoni]].<ref>{{cite web |title=Emcure Pharmaceuticals - Crunchbase Company Profile |url=https://www.crunchbase.com/organization/emcure-pharmaceuticals |website=Crunchbase |access-date=26 May 2025}}</ref>
| 2013 || Launched health foods venture in partnership with cricketer [[MS Dhoni]].<ref>{{cite web |title=Emcure Pharmaceuticals - Crunchbase Company Profile |url=https://www.crunchbase.com/organization/emcure-pharmaceuticals |website=Crunchbase |access-date=26 May 2025}}</ref>
Line 83: Line 83:


== Business Model ==
== Business Model ==
Emcure Pharmaceuticals operates a diversified business model, generating revenue through the development, manufacturing, and global marketing of pharmaceutical products. Its primary customer segments include healthcare providers, hospitals, and retail pharmacies in India and over 70 countries, with key markets in Europe, Canada, and the [[Rest of the World (RoW)]]. The company focuses on generics, biotherapeutics, and complex APIs, leveraging its research and development capabilities to launch differentiated products. Approximately 46.84% of its FY 2023 revenue came from international markets, with 30% from regulated markets like Canada and Europe, and the rest from contract manufacturing and other segments. Emcure also engages in strategic partnerships with multinational corporations for in-licensing and technology transfers, enhancing its product portfolio and market reach.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder | IPO | Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref><ref>{{cite web |title=Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details |url=https://groww.in/ipo/emcure-pharma-ipo |website=Groww |date=5 July 2024 |access-date=26 May 2025}}</ref>
Emcure Pharmaceuticals operates a diversified business model, generating revenue through the development, manufacturing, and global marketing of pharmaceutical products. Its primary customer segments include healthcare providers, hospitals, and retail pharmacies in India and over 70 countries, with key markets in Europe, Canada, and the [[Rest of the World (RoW)]]. The company focuses on generics, biotherapeutics, and complex APIs, leveraging its research and development capabilities to launch differentiated products. Approximately 46.84% of its FY 2023 revenue came from international markets, with 30% from regulated markets like Canada and Europe, and the rest from contract manufacturing and other segments. Emcure also engages in strategic partnerships with multinational corporations for in-licensing and technology transfers, enhancing its product portfolio and market reach.<ref>{{cite web |title=Emcure Pharmaceuticals: Founder, IPO, Subsidiaries |url=https://startuptalky.com/emcure-pharmaceuticals/ |website=StartupTalky |date=12 July 2024 |access-date=26 May 2025}}</ref><ref>{{cite web |title=Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details |url=https://groww.in/ipo/emcure-pharma-ipo |website=Groww |date=5 July 2024 |access-date=26 May 2025}}</ref>


== Products / Services ==
== Products / Services ==

Latest revision as of 10:20, 26 May 2025

Emcure Pharmaceuticals
Company typePublic
BSE: 544210 NSE: EMCURE
IndustryPharmaceuticals
FoundedApril 15, 1981; 44 years ago (1981-04-15)
FounderSatish Ramanlal Mehta
HeadquartersPlot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi,
Pune, Maharashtra
,
India
Area served
Worldwide
Key people
  • Satish Ramanlal Mehta (CEO & MD)
  • Namita Thapar (Whole Time Director)
  • Sunil Rajanikant Mehta (Whole Time Director)
  • Samit Satish Mehta (Whole Time Director)
  • Berjis Minoo Desai (Chairman)
ProductsTablets, capsules, injectables, biotherapeutics, active pharmaceutical ingredients (APIs)
Revenue₹7,896 crore (FY 2025)
₹707 crore (FY 2025)
Number of employees
6733 (January 2025)
Websitewww.emcure.com

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Established in 1981, it develops, manufactures, and markets a wide range of pharmaceutical products, including generics, biotherapeutics, and active pharmaceutical ingredients (APIs) across therapeutic areas such as gynaecology, cardiology, oncology, HIV, and blood-related disorders. The company operates in over 70 countries, with a strong presence in India, Europe, and Canada. Emcure is recognised as the 12th largest pharmaceutical company in India by domestic sales (AIOCD-AWACS, June 2024) and is known for its research-driven approach, with approximately 500 scientists contributing to its innovation pipeline. In 2024, Emcure launched its initial public offering (IPO), listing on the BSE and NSE.[1][2]

Founders & Leadership

Emcure Pharmaceuticals was founded by Satish Ramanlal Mehta, who serves as the CEO and Managing Director. Mehta, a postgraduate in Chemistry from Pune University and a diploma holder in management from IIM Ahmedabad, started Emcure with a ₹3 lakh bank loan in 1981. His leadership transformed the company from a contract manufacturer to a global player in generics and biotherapeutics. Notable achievements include establishing Emcure as a leader in gynaecology and HIV antivirals in India and forging partnerships with global pharmaceutical companies like Bristol-Myers Squibb and Roche. The leadership team includes Namita Thapar (Whole Time Director), Sunil Rajanikant Mehta (Whole Time Director), Samit Satish Mehta (Whole Time Director), and Berjis Minoo Desai (Chairman).[3][4]

Origin & Founding Story

Namita Thapar, the Executive director of Emcure Pharmaceuticals

Emcure Pharmaceuticals was founded in 1981 by Satish Ramanlal Mehta in Pune, Maharashtra. Starting as a contract manufacturer for multinational pharmaceutical companies, Mehta leveraged his education from IIM Ahmedabad and family business background to pivot Emcure towards developing branded generic formulations. With an initial bank loan of ₹3 lakh, Mehta built a company focused on innovation, particularly in complex APIs and biotherapeutics. By the 1990s, Emcure transitioned into producing generics, and by 2006, it secured licensing agreements with global giants like Bristol-Myers Squibb and Gilead Sciences. The company’s emphasis on research and development, coupled with strategic partnerships, enabled its expansion into over 70 countries.[5][6]

Timeline

Year Milestone
1981 Emcure Pharmaceuticals founded by Satish Ramanlal Mehta in Pune with a ₹3 lakh bank loan.[7]
1990s Transitioned from contract manufacturing to producing generic drugs.[8]
2006 Signed licensing agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir.[9]
2006 Received US FDA approval for solid dosage facility at Hinjawadi, Pune.[10]
2012 Signed agreement with Roche to manufacture anticancer drugs Herceptin and Mabthera in India.[11]
2013 Launched health foods venture in partnership with cricketer MS Dhoni.[12]
2014 Bain Capital acquired 13% stake from Blackstone.[13]
2021 Demerged US-based business into Avet Lifesciences.[14]
2024 Launched IPO, raising $234 million, listed on BSE and NSE.[15]
2025 Incorporated wholly-owned subsidiary Emcure Generics Private Limited.[16]

Funding

Date Round Amount Investors
2006 Private Equity Undisclosed Blackstone[17]
2014 Private Equity Undisclosed Bain Capital (acquired 13% stake from Blackstone)[18]
2024 IPO $234 million Public investors[19]

Business Model

Emcure Pharmaceuticals operates a diversified business model, generating revenue through the development, manufacturing, and global marketing of pharmaceutical products. Its primary customer segments include healthcare providers, hospitals, and retail pharmacies in India and over 70 countries, with key markets in Europe, Canada, and the Rest of the World (RoW). The company focuses on generics, biotherapeutics, and complex APIs, leveraging its research and development capabilities to launch differentiated products. Approximately 46.84% of its FY 2023 revenue came from international markets, with 30% from regulated markets like Canada and Europe, and the rest from contract manufacturing and other segments. Emcure also engages in strategic partnerships with multinational corporations for in-licensing and technology transfers, enhancing its product portfolio and market reach.[20][21]

Products / Services

Emcure Pharmaceuticals offers a diverse portfolio of pharmaceutical products across multiple therapeutic areas:

  • Tablets and Capsules: Includes oral solids and liquids for gynaecology, cardiology, oncology, HIV, and anti-infectives. Notable brands include Maxtra, Metpure, and Asomex.[22]
  • Injectables: Includes liposomal and lyophilised injectables, such as Elaxim and Hamsyl, used in cardiology and oncology.[23]
  • Biotherapeutics: Through its subsidiary Gennova Biopharmaceuticals, Emcure has launched six biologics, including Elaxim, Tenectase, and Vintor, focusing on cardiology, nephrology, and oncology.[24]
  • Active Pharmaceutical Ingredients (APIs): Manufactures complex APIs, including chiral molecules and cytotoxic products.[25]
  • Health Foods: Launched a venture in 2013 with MS Dhoni to offer nutritional products.[26]

Growth & Metrics

Emcure Pharmaceuticals has demonstrated significant growth, with a trailing 12-month revenue of $893 million (approximately ₹7896 crore) and a net profit of ₹707 crore in FY 2025.[27] The company reported a 19.5% year-on-year revenue increase to ₹2116 crore in Q4 FY 2025, with a 63% rise in net profit to ₹197 crore.[28] Its market capitalisation stands at ₹24,337 crore as of May 2025.[29] Emcure employs 6733 people (January 2025) and has a global presence in over 70 countries, with 350+ brands and 13 manufacturing facilities in India.[30] The company’s domestic business grew by 12% in Q3 FY 2025, while international sales surged by 25%.[31]

Legal Entity Information

Field Details
Legal Name Emcure Pharmaceuticals Limited
Foundation Date 15 April 1981
Registrar of Companies ROC Pune
Corporate Identification Number (CIN) U24231PN1981PLC024251
Registered Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, Maharashtra 411057
Email ID investors@emcure.com
Company Status Active
Directors
  • Berjis Minoo Desai
  • Satish Ramanlal Mehta
  • Sunil Rajanikant Mehta
  • Namita Vikas Thapar
  • Samit Satish Mehta
  • 2 others
Authorized Share Capital ₹2,000,000,000
Paid-up Capital ₹1,808,521,160

[32][33]

Acquisitions and Investments

  • Demerger: In 2021, Emcure demerged its US-based business, including subsidiary Heritage Pharmaceuticals, into Avet Lifesciences.[34]
  • Investment: In 2025, an Emcure executive participated in a $3 million investment round for Medulance, a healthcare startup.[35]
  • Subsidiary Formation: In May 2025, Emcure incorporated Emcure Generics Private Limited, a wholly-owned subsidiary focused on manufacturing and distributing pharmaceuticals.[36]

Media & Public Recognition

Emcure Pharmaceuticals has received significant recognition for its contributions to the pharmaceutical industry. It was ranked the 12th largest pharmaceutical company in India by domestic sales (AIOCD-AWACS, June 2024).[37] The company’s IPO in 2024, raising $234 million, drew $11 billion in bids, reflecting strong market confidence.[38] Emcure’s executive Namita Thapar gained public attention as a judge on Shark Tank India, advocating for work-life balance.[39] However, the company faced scrutiny for a 2016 US FDA warning letter regarding data integrity issues and a 2019 DOJ settlement involving its former subsidiary Heritage Pharmaceuticals.[40]

FAQs

What is Emcure Pharmaceuticals known for?
Emcure is known for developing, manufacturing, and marketing generics, biotherapeutics, and APIs across therapeutic areas like gynaecology, cardiology, oncology, and HIV.[41]
Where does Emcure operate?
The company operates in over 70 countries, with key markets in India, Europe, Canada, and the Rest of the World (RoW).[42]
What was the purpose of Emcure’s 2024 IPO?
The IPO raised $234 million to fund debt repayment and corporate purposes, strengthening its financial position.[43]
Who founded Emcure Pharmaceuticals?
Emcure was founded by Satish Ramanlal Mehta in 1981, who remains the CEO and Managing Director.[44]

External Links

Related Startups

References

  1. ↑ "Emcure Pharmaceuticals". Emcure. Retrieved 26 May 2025.
  2. ↑ "Emcure Pharmaceuticals 2025 Company Profile". PitchBook. Retrieved 26 May 2025.
  3. ↑ "How Emcure Pharma owner built a Rs 6,000 Cr business empire". YourStory. 19 August 2021. Retrieved 26 May 2025.
  4. ↑ "Emcure Pharmaceuticals Ltd Company Profile". Moneycontrol. Retrieved 26 May 2025.
  5. ↑ "Emcure Pharmaceuticals: Founder, IPO, Subsidiaries". StartupTalky. 12 July 2024. Retrieved 26 May 2025.
  6. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  7. ↑ "How Emcure Pharma owner built a Rs 6,000 Cr business empire". YourStory. 19 August 2021. Retrieved 26 May 2025.
  8. ↑ "Emcure Pharmaceuticals: Founder, IPO, Subsidiaries". StartupTalky. 12 July 2024. Retrieved 26 May 2025.
  9. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  10. ↑ "Emcure Pharmaceuticals". Emcure. Retrieved 26 May 2025.
  11. ↑ "Emcure Pharmaceuticals: Founder, IPO, Subsidiaries". StartupTalky. 12 July 2024. Retrieved 26 May 2025.
  12. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  13. ↑ "How Emcure Pharma owner built a Rs 6,000 Cr business empire". YourStory. 19 August 2021. Retrieved 26 May 2025.
  14. ↑ "Rating Rationale". CRISIL. 19 July 2024. Retrieved 26 May 2025.
  15. ↑ "Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details". Groww. 5 July 2024. Retrieved 26 May 2025.
  16. ↑ "Emcure Pharmaceuticals announced the incorporation of a wholly-owned subsidiary". BrightStake. 23 May 2025. Retrieved 26 May 2025.
  17. ↑ "How Emcure Pharma owner built a Rs 6,000 Cr business empire". YourStory. 19 August 2021. Retrieved 26 May 2025.
  18. ↑ "How Emcure Pharma owner built a Rs 6,000 Cr business empire". YourStory. 19 August 2021. Retrieved 26 May 2025.
  19. ↑ "Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details". Groww. 5 July 2024. Retrieved 26 May 2025.
  20. ↑ "Emcure Pharmaceuticals: Founder, IPO, Subsidiaries". StartupTalky. 12 July 2024. Retrieved 26 May 2025.
  21. ↑ "Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details". Groww. 5 July 2024. Retrieved 26 May 2025.
  22. ↑ "Presence in Indian Pharmaceutical Market". Emcure. 29 July 2021. Retrieved 26 May 2025.
  23. ↑ "Emcure Pharmaceuticals Ltd Company Profile". GlobalData. Retrieved 26 May 2025.
  24. ↑ "Emcure Pharmaceuticals Ltd Company Profile". GlobalData. Retrieved 26 May 2025.
  25. ↑ "Emcure Pharmaceuticals". Emcure. Retrieved 26 May 2025.
  26. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  27. ↑ "Emcure Pharmaceuticals 2025 Company Profile". PitchBook. Retrieved 26 May 2025.
  28. ↑ "Emcure Pharmaceuticals achieves 63% profit growth". Webindia123. 22 May 2025. Retrieved 26 May 2025.
  29. ↑ "Emcure Pharmaceuticals Ltd share price". Screener. Retrieved 26 May 2025.
  30. ↑ "Emcure Pharmaceuticals Limited - 2025 Financials & Shareholding". Tracxn. 15 April 2025. Retrieved 26 May 2025.
  31. ↑ "Emcure Pharmaceuticals Q3FY25: Profit grows 35.4%". Business Standard. 6 February 2025. Retrieved 26 May 2025.
  32. ↑ "Emcure Pharmaceuticals Limited - 2025 Financials & Shareholding". Tracxn. 15 April 2025. Retrieved 26 May 2025.
  33. ↑ "Emcure Pharmaceuticals Ltd Company Profile". Moneycontrol. Retrieved 26 May 2025.
  34. ↑ "Rating Rationale". CRISIL. 19 July 2024. Retrieved 26 May 2025.
  35. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  36. ↑ "Emcure Pharmaceuticals announced the incorporation of a wholly-owned subsidiary". BrightStake. 23 May 2025. Retrieved 26 May 2025.
  37. ↑ "Emcure Pharmaceuticals". Emcure. Retrieved 26 May 2025.
  38. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  39. ↑ "In a fiery debate on work-life balance". The Economic Times. 22 December 2024. Retrieved 26 May 2025.
  40. ↑ "Emcure Pharmaceuticals - Crunchbase Company Profile". Crunchbase. Retrieved 26 May 2025.
  41. ↑ "Emcure Pharmaceuticals". Emcure. Retrieved 26 May 2025.
  42. ↑ "Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details". Groww. 5 July 2024. Retrieved 26 May 2025.
  43. ↑ "Emcure Pharma IPO - Check Issue Date, Price, Lot Size & Details". Groww. 5 July 2024. Retrieved 26 May 2025.
  44. ↑ "How Emcure Pharma owner built a Rs 6,000 Cr business empire". YourStory. 19 August 2021. Retrieved 26 May 2025.
Retrieved from "http://startupwiki.ai/index.php?title=Emcure_Pharmaceuticals&oldid=7782"